

Jan Delaval please

Access DB#

# SEARCH REQUEST FORM

59923

Scientific and Technical Information Center

Requester's Full Name: Sabine Ozz Examiner #: 74141 Date: 2/5/02  
Art Unit: 1616 Phone Number 30 5-3910 Serial Number: 09/899,702 & 09/779,331  
Mail Box and Bldg/Room Location: 2D19, 4M Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. MEJ

\*\*\*\*\*  
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Estrogenic Compds as Antiangiogenic agents  
Inventors (please provide full names): D'Amato et al.

Earliest Priority Filing Date: 7/5/01

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Pl. note 09/899,702 contains NO R<sub>h</sub>, + R<sub>h</sub>

Substituted

Elected species

09/899,702

compd of clom

09/779,331

compd of cl 8

Jan Delaval  
Reference Librarian  
Biotechnology & Chemical Library  
CM1 JE07 - 703-308-4498  
jan.delaval@uspto.gov

(STIC)

RECEIVED  
JAN - 8 2002

Please see attached sheets

thank you

## STAFF USE ONLY

Searcher: Jan  
Searcher Phone #: 4498  
Searcher Location: \_\_\_\_\_  
Date Searcher Picked Up: 2/15/02  
Date Completed: 2/15/02  
Searcher Prep & Review Time: \_\_\_\_\_  
Clerical Prep Time: 25  
Online Time: 75

## Type of Search

NA Sequence (#) \_\_\_\_\_  
AA Sequence (#) \_\_\_\_\_  
Structure (#) ☒ \_\_\_\_\_  
Bibliographic \_\_\_\_\_  
Litigation \_\_\_\_\_  
Fulltext \_\_\_\_\_  
Patent Family \_\_\_\_\_  
Other \_\_\_\_\_

## Vendors and cost where applicable

STN ☒ \_\_\_\_\_  
Dialog \_\_\_\_\_  
Questel/Orbit \_\_\_\_\_  
Dr. Link \_\_\_\_\_  
Lexis/Nexis \_\_\_\_\_  
Sequence Systems \_\_\_\_\_  
WWW/Internet \_\_\_\_\_  
Other (specify) \_\_\_\_\_

=> fil reg

FILE 'REGISTRY' ENTERED AT 15:28:37 ON 19 FEB 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 18 FEB 2002 HIGHEST RN 393508-26-4

DICTIONARY FILE UPDATES: 18 FEB 2002 HIGHEST RN 393508-26-4

Jan Delaval  
Reference Librarian  
Biotechnology & Chemical Library  
CM1 1E07-703-308-4498  
jan.delaval@uspto.gov

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.


Calculated physical property data is now available. See HELP PROPERTIES  
for more information. See STNote 27, Searching Properties in the CAS  
Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

The P indicator for Preparations was not generated for all of the  
CAS Registry Numbers that were added to the H/Z/CA/CAplus files between  
12/27/01 and 1/23/02. Use of the P indicator in online and SDI searches  
during this period, either directly appended to a CAS Registry Number  
or by qualifying an L-number with /P, may have yielded incomplete results.  
As of 1/23/02, the situation has been resolved. Also, note that searches  
conducted using the PREP role indicator were not affected.

Customers running searches and/or SDIs in the H/Z/CA/CAplus files  
incorporating CAS Registry Numbers with the P indicator between 12/27/01  
and 1/23/02, are encouraged to re-run these strategies. Contact the  
CAS Help Desk at 1-800-848-6533 in North America or 1-614-447-3698,  
worldwide, or send an e-mail to [help@cas.org](mailto:help@cas.org) for further assistance or to  
receive a credit for any duplicate searches.

=> d sta que 129

L13 32 SEA FILE=REGISTRY ABB=ON PLU=ON (1035-77-4/BI OR 117048-59-6/  
BI OR 1236-72-2/BI OR 15833-07-5/BI OR 16205-32-6/BI OR  
165619-07-8/BI OR 165619-10-3/BI OR 165619-11-4/BI OR 165619-22  
-7/BI OR 165619-23-8/BI OR 192062-02-5/BI OR 192062-12-7/BI OR  
192062-13-8/BI OR 192062-14-9/BI OR 192062-15-0/BI OR 192062-20  
-7/BI OR 22415-44-7/BI OR 26788-23-8/BI OR 26890-04-0/BI OR  
302799-37-7/BI OR 362-07-2/BI OR 362-08-3/BI OR 383414-35-5/BI  
OR 50-27-1/BI OR 50-28-2/BI OR 518-28-5/BI OR 53-16-7/BI OR  
56-53-1/BI OR 57-63-6/BI OR 5976-67-0/BI OR 64-86-8/BI OR  
95041-90-0/BI)  
L14 27 SEA FILE=REGISTRY ABB=ON PLU=ON L13 AND C5-C6-C6-C6/ES  
L16 STR



N~N~N  
@30 31 32

C≡C—G3  
@33 34 35

Ak—Cy  
@36 @37

C=C—G3  
@38 39 40

Ak—C=C  
@41 42 43

Cy—C=C  
@44 45 46

Ak—Cy—C=C  
@50 47 48 49

C≡C  
@51 52














O—G3  
@53 54

Ak—G4  
@55 56

VAR G1=H/X/CN/AK/OH/22/NH2/24/26  
VAR G2=30/CN/33/38/41/44/50/51/53/55/62/65/66  
VAR G3=AK/CY/36  
VAR G4=OH/NH2/X/58  
VAR G5=AK/CY/36-66 37-68  
NODE ATTRIBUTES:  
CONNECT IS M1 RC AT 1  
CONNECT IS M1 RC AT 7  
CONNECT IS M1 RC AT 15  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 67

STEREO ATTRIBUTES: NONE  
L18 394 SEA FILE=REGISTRY CSS FUL L16  
L19 STR



VAR G1=C/18/20/23/26

VAR G2=C/31/34/36/39/45/47/49/52

VAR G3=AK/CY/43

NODE ATTRIBUTES:

CONNECT IS M1 RC AT 2

CONNECT IS M1 RC AT 3

CONNECT IS M1 RC AT 4

CONNECT IS M1 RC AT 14

CONNECT IS M1 RC AT 15

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RSPEC 1

NUMBER OF NODES IS 53

STEREO ATTRIBUTES: NONE

L21 152 SEA FILE=REGISTRY SUB=L18 CSS FUL L19

L22 STR



VAR G1=C/25/19/22/27/33/37/39/42/46

VAR G2=AK/CY/31

NODE ATTRIBUTES:

CONNECT IS M1 RC AT 1

CONNECT IS M1 RC AT 2

CONNECT IS M1 RC AT 3

CONNECT IS M1 RC AT 4

CONNECT IS M1 RC AT 7

CONNECT IS M1 RC AT 14

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 1

NUMBER OF NODES IS 46

STEREO ATTRIBUTES: NONE

L24 88 SEA FILE=REGISTRY SUB=L21 CSS FUL L22

L25 13 SEA FILE=REGISTRY ABB=ON PLU=ON L14 AND L24

L27 75 SEA FILE=REGISTRY ABB=ON PLU=ON L24 NOT L25

L28 68 SEA FILE=REGISTRY ABB=ON PLU=ON L27 NOT (IDS/CI OR (D OR T)/ELS OR 11C# OR 13C# OR 14C#)

L29 81 SEA FILE=REGISTRY ABB=ON PLU=ON (L25 OR L28)

=> d his

(FILE 'HOME' ENTERED AT 14:20:04 ON 19 FEB 2002)  
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 14:20:15 ON 19 FEB 2002

E DAMATO/AU

E D AMATO/AU

L1 65 S E74,E77,E84,E86,E87

E AMATO/AU

L2 2 S E36

L3 28 S E133,E135,E140,E141

E VARMA R/AU

L4 124 S E3,E10,E11,E12

L5 133 S E45-E47

E HAUGWITZ R/AU

L6 147 S E3-E11

E CUSHMAN M/AU

L7 201 S E3-E6,E8,E9,E10  
 L8 685 S L1-L7  
 L9 14 S L8 AND ?ESTROGEN?  
 L10 42 S L8 AND ?ANGIO?  
 L11 4 S L9 AND L10  
 L12 1 S L11 AND ESTROGEN?/TI  
 SEL RN

FILE 'REGISTRY' ENTERED AT 14:24:13 ON 19 FEB 2002

L13 32 S E1-E32  
 L14 27 S L13 AND C5-C6-C6-C6/ES  
 L15 1 S L14 AND C21H28O2  
 E C21H28O2/MF  
 L16 STR  
 L17 9 S L16 CSS SAM  
 L18 394 S L16 CSS FUL  
 SAV L18 QAZ899/A  
 L19 STR  
 L20 5 S L19 CSS SAM SUB=L18  
 L21 152 S L19 CSS FUL SUB=L18  
 SAV L21 QAZ899A/A  
 L22 STR  
 L23 4 S L22 CSS SAM SUB=L21  
 L24 88 S L22 CSS FUL SUB=L21  
 SAV L24 QAZ899B/A  
 L25 13 S L14 AND L24  
 L26 14 S L14 NOT L25  
 L27 75 S L24 NOT L25  
 L28 68 S L27 NOT (IDS/CI OR (D OR T)/ELS OR 11C# OR 13C# OR 14C#)  
 L29 81 S L25,L28  
 L30 80 S L29 NOT L15  
 SAV L30 QAZ899C/A

*Species*

FILE 'HCAOLD' ENTERED AT 15:15:35 ON 19 FEB 2002

L31 0 S L15  
 L32 72 S L30

FILE 'HCAPLUS' ENTERED AT 15:15:58 ON 19 FEB 2002

L33 2 S L15  
 L34 2 S L8 AND L33  
 L35 489 S L30  
 E ANGIOGENESIS/CT  
 E E3+ALL  
 L36 5343 S E5+NT  
 E E10+ALL  
 L37 1959 S E4+NT  
 L38 73654 S E3+NT  
 E E3+ALL  
 L39 77026 S E4  
 L40 165292 S E501+NT  
 L41 13 S L35 AND L36  
 L42 83 S L35 AND L37-L41  
 L43 38 S L35 AND ANGIOGENES?  
 L44 3 S L35 AND ANTIANGIOGENES?  
 L45 15 S L35 AND ANTIANGIO?  
 L46 39 S L41,L43-L45  
 L47 33 S L42 AND L46  
 L48 49 S L35 AND P/DT  
 L49 358 S L35 AND ?ESTROGEN?  
 L50 67 S L49 AND L41-L48  
 L51 19 S L50 AND L46  
 L52 30 S L35 AND ANGIO?/CW  
 L53 29 S L52 AND L41-L48,L50,L51  
 L54 30 S L34,L53  
 L55 30 S L54 AND L33-L54  
 L56 2 S L55 AND L34

*Species*

L57 28 S L55 NOT L56  
L58 81 S L41-L48, L50-L55 NOT L57  
L59 64 S L30 (L) THU/RL  
L60 36 S L59 AND L58  
L61 16 S L60 AND (1 OR 63)/SC  
L62 13 S L60 AND (1 OR 63)/SX  
L63 24 S L61, L62  
L64 24 S L59 AND ?ANGIO?  
L65 24 S L64 AND L33-L63  
L66 23 S L65 NOT 27/SC  
L67 24 S L33, L34, L66 AND L33-L66  
SEL HIT RN

FILE 'REGISTRY' ENTERED AT 15:28:10 ON 19 FEB 2002

L68 17 S E1-E17  
L69 16 S L68 NOT L15


← hit compounds for  
L67, 1-24

FILE 'REGISTRY' ENTERED AT 15:28:37 ON 19 FEB 2002

=> d ide can l15

L15 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN 165619-11-4 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(1E)-1-propenyl-, (17.beta.)- (9CI)  
(CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(1-propenyl)-, [2(E),17.beta.] -  
OTHER NAMES:  
CN NSC 667047  
FS STEREOSEARCH  
MF C21 H28 O2  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.  
Double bond geometry as shown.



Species

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

REFERENCE 2: 123:112496

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 15:28:54 ON 19 FEB 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.



FILE COVERS 1907 - 18 Feb 2002 VOL 136 ISS 8  
FILE LAST UPDATED: 17 Feb 2002 (20020217/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d 170 bib abs hitrn tot

L70 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2002 ACS  
AN 2002:11127 HCAPLUS  
DN 136:64669  
TI **Estrogenic** compounds as **antiangiogenic** agents  
IN D'Amato, Robert J.; Varma, Ravi K.; Haugwitz, Rudiger G.; Cushman, Mark  
PA USA  
SO U.S. Pat. Appl. Publ., 14 pp., Cont. of U.S. Ser. No. 154,322, abandoned.  
CODEN: USXXCO  
DT **Patent**  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002002294	A1	20020103	US 2001-899702	20010705
PRAI	US 1997-59916	P	19970924		
	US 1998-154322	B1	19980916		
OS	MARPAT 136:64669				
GI					



AB 2-Methoxyestradiol derivs., such as I [R1, R3 = H, Cl, Br, I, F, CN, alkyl, OH, CH2OH, NH2, alkylamino; R2 = N3, CN, C.tplbond.CR, C=CHR, RCH=CH2, C.tplbond.CH, OR, R-R1, OR-R1 (R = alkyl, R1 = OH, NH2, Cl, Br, I, F, CF3); Z = CH, COH, CR2-OH (R2 = alkyl, aralkyl); Z' = CH2, CO, CH(OH); C=NOH, C=NOR5, CHC.tplbond.N, CHNR5R5 (R5 = H, alkyl, aralkyl)], were used for treating mammalian disease characterized by undesirable **angiogenesis**. Thus, 2-methoxyestradiol (II) showed inhibition of tubulin polymn. (IC50 = 3.6.+-.0.4 .mu.M), inhibition of colchicine binding to tubulin (1.9.+-.0.2 .mu.M) and antitumor activity against breast, CNS, melanoma, ovarian tumor cell assay in vitro.



- IT 362-07-2, NSC 659853 362-08-3, 2-Methoxyestrone  
22415-44-7 165619-07-8, NSC 671043 165619-11-4  
, NSC 667047 192062-02-5, NSC 682429 192062-12-7, NSC  
679431 192062-13-8, NSC 681684 192062-14-9, NSC 680185  
192062-15-0, NSC 681683 192062-20-7, NSC 683125  
302799-37-7, NSC 683688 383414-35-5, NSC 678473  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological  
activity); THU (Therapeutic use); BIOL (Biological study); USES  
(Uses)  
(estrogenic compds. as antiangiogenic agents)
- L70 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2002 ACS  
AN 1995:592276 HCAPLUS  
DN 123:112496  
TI Synthesis, Antitubulin and Antimitotic Activity, and Cytotoxicity of  
Analogues of 2-Methoxyestradiol, an Endogenous Mammalian Metabolite of  
Estradiol That Inhibits Tubulin Polymerization by Binding to the  
Colchicine Binding Site  
AU Cushman, Mark; He, Hu-Ming; Katzenellenbogen, John A.; Lin, Chii  
M.; Hamel, Ernest  
CS Department of Medicinal Chemistry, Purdue University, West Lafayette, IN,  
47907, USA  
SO J. Med. Chem. (1995), 38(12), 2041-9  
CODEN: JMCMAR; ISSN: 0022-2623  
DT Journal  
LA English  
AB In order to define the structural parameters assocd. with the antitubulin  
activity and cytotoxicity of 2-methoxyestradiol, a mammalian metabolite of  
estradiol, an array of analogs was synthesized and evaluated. The  
potencies of the new congeners as inhibitors of tubulin polymn. and  
colchicine binding were detd. using tubulin purified from bovine brain,  
and the cytotoxicities of the new compds. were studied in a variety of  
cancer cell cultures. Maximum antitubulin activity was obsd. in  
estradiols having unbranched chain substituents at the 2-position with  
three non-hydrogen atoms. 2-Ethoxyestradiol and 2-((E)-1-  
propenyl)estradiol were substantially more potent than 2-methoxyestradiol  
itself. The tubulin polymn. inhibitors in this series displayed  
significantly higher cytotoxicities in the MDA-MB-435 breast cancer cell  
line than in the other cell lines studied. The potencies of the analogs  
as cytotoxic and antimitotic agents in cancer cell cultures correlated  
with their potencies as inhibitors of tubulin polymn., supporting the  
hypothesis that inhibition of tubulin polymn. is the mechanism of the  
cytotoxic action of 2-methoxyestradiol and its congeners. Several of the  
more potent analogs were tested in an **estrogen** receptor binding  
assay, and their affinities relative to estradiol were found to be very  
low.
- IT 165619-11-4P 165619-12-5P 165619-13-6P  
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);  
SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(synthesis, antitubulin and antimitotic activity, and cytotoxicity of  
analogs of methoxyestradiol)
- IT 362-07-2P 165619-07-8P 165619-08-9P  
165619-09-0P  
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic  
preparation); BIOL (Biological study); PREP (Preparation)  
(synthesis, antitubulin and antimitotic activity, and cytotoxicity of  
analogs of methoxyestradiol)

=> d 171 bib abs hitrn tot

- L71 ANSWER 1 OF 22 HCAPLUS COPYRIGHT 2002 ACS  
AN 2001:798040 HCAPLUS  
DN 135:339222  
TI Inhibition of abnormal cell proliferation with camptothecin or a  
derivative, analog, metabolite, or prodrug thereof, and combinations

including camptothecin  
 IN Rubinfeld, Joseph  
 PA Supergen, Inc., USA  
 SO PCT Int. Appl., 38 pp.  
 CODEN: PIXXD2

DT **Patent**  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001080843	A2	20011101	WO 2001-US12848	20010419
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2000-553710 A1 20000420

AB A method for treating diseases assocd. with abnormal cell proliferation comprises delivering to a patient in need of treatment a compd. selected from 20(S)-camptothecin, an analog of 20(S)-camptothecin, a deriv. of 20(S)-camptothecin, a prodrug of 20(S)-camptothecin, and pharmaceutically active metabolite of 20(S)-camptothecin, in combination with an effective amt. of one or more agents selected form the group consisting of alkylating agent, antibiotic agent, antimetabolic agent, hormonal agent, plant-derived agent, anti-**angiogenesis** agent and biol. agent. The method can be used to treat benign tumors, malignant or metastatic tumors, leukemia and diseases assocd. with abnormal **angiogenesis**

IT **362-07-2, 2-Methoxyestradiol**  
 RL: BAC (Biological activity or effector, except adverse); **THU**  
**(Therapeutic use)**; BIOL (Biological study); USES (Uses)  
 (camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

L71 ANSWER 2 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:769051 HCAPLUS

DN 136:112738

TI 2-Methoxyestradiol: A novel endogenous chemotherapeutic and anti-**angiogenic** agent

AU Pribluda, Victor S.; LaVallee, Theresa M.; Green, Shawn J.

CS EntreMed, Rockville, MD, USA

SO New Angiotherapy (2002), 387-407. Editor(s): Fan, Tai-Ping D.; Kohn, Elise C. Publisher: Humana Press Inc., Totowa, N. J.

CODEN: 69BYCE

DT Conference; General Review

LA English

AB A review which discusses the properties of 2-methoxyestradiol, which is a part of a new generation of anti-cancer agents. The 2-methoxyestradiol is now recognized as a potent endogenous antimitogen and has the ability to selectively inhibit the growth of rapidly proliferating endothelial cells. Its candidacy as a viable antimitotic drug is supported by exptl. evidence showing that 2-methoxyestradiol is orally-active, and at therapeutic doses shows minimal, if any, toxicity.

IT **362-07-2, 2-Methoxyestradiol**  
 RL: BSU (Biological study, unclassified); **THU (Therapeutic use)**;  
 BIOL (Biological study); USES (Uses)  
 (methoxyestradiol as chemotherapeutic and anti-**angiogenic** agent)

RE.CNT 108 THERE ARE 108 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 3 OF 22 HCAPLUS COPYRIGHT 2002 ACS  
AN 2001:746919 HCAPLUS  
DN 136:31843  
TI **Angiogenetic** and anti-**angiogenetic** effects of  
estradiol and its metabolites  
AU Mueck, A. O.; Seeger, H.; Lippert, C.; Wallwiener, D.  
CS Section of Endocrinology and Menopause, University Hospital, Tuebingen, 72  
076, Germany  
SO Journal of Clinical and Basic Cardiology (2001), 4(2), 153-155  
CODEN: JCBCFT; ISSN: 1561-2775  
PB Krause & Pachernegg GmbH  
DT Journal  
LA English  
AB Atherosclerotic plaques in later stages exhibit marked presence of new  
micro vessels. Thus **angiogenesis** may be important for the  
development of atherosclerotic plaques and long-term anti-  
**angiogenetic** therapy may present an effective new  
anti-atherosclerotic approach. 2-Methoxyestradiol, an endogenous  
estradiol metabolite, has already been shown to be an effective anti-  
**angiogenetic** substance. In the present study 14 endogenous  
estradiol metabolites were tested on their **angiogenetic** and  
anti-**angiogenetic** properties and compared to the effect of their  
parent substance, 17.beta.-estradiol. Endothelial cells from human  
umbilical veins were used for the expts. 17.beta.-Estradiol showed a  
biphasic reaction on the proliferation of vascular endothelial cells. At  
low concn. it stimulated and at high concns. it inhibited cell growth.  
The same pattern was obsd. for the hydroxylated A-ring metabolites.  
Methylation of these metabolites, however, completely abrogated the  
anti-proliferative effect at high concns., except for the metabolite  
2-hydroxyestradiol. For the D-ring metabolites no marked changes were  
obsd. These results indicate that in addn. to 2-methoxyestradiol other  
endogenous estradiol metabolites are potent anti-**angiogenetic**  
substances at high dosages. Since some of these metabolites are almost  
devoid of any **estrogenic** property, they may be useful for  
long-term anti-**angiogenetic** therapy in both men and women. This  
should be of interest to clin. pharmacol. research since it points to  
potential new aspects in the treatment of cardiovascular diseases.  
IT 362-07-2, 2-Methoxyestradiol 362-08-3, 2-Methoxyestrone  
RL: PAC (Pharmacological activity); PRP (Properties); THU  
(**Therapeutic use**); BIOL (Biological study); USES (Uses)  
(**angiogenesis** and anti-**angiogenesis** effects of  
estradiol and metabolites)  
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 4 OF 22 HCAPLUS COPYRIGHT 2002 ACS  
AN 2001:360984 HCAPLUS  
DN 135:56155  
TI Oestradiol metabolites: Effects on airway remodelling  
AU Stewart, A. G.; Vlahos, R.; Fernandes, D. J.; Hughes, R. A.  
CS Department of Pharmacology, University of Melbourne, Australia  
SO Prog. Respir. Res. (2001), 31(New Drugs for Asthma, Allergy and COPD),  
102-105  
CODEN: PRRRAE; ISSN: 1422-2140  
PB S. Karger AG  
DT Journal; General Review  
LA English  
AB A review with 25 refs. Airway wall remodelling is a significant  
contributor to the airway hyperresponsiveness in asthma and hence to  
asthma symptoms. Existing anti-asthma agents (glucocorticoids) appear to  
have insufficient efficacy in the regulation of smooth muscle  
proliferation and other aspects of airway wall remodelling in severe  
asthma. Thus, agents that regulate airway wall remodelling will add  
significantly to the choice of preventative therapies available for more  
severe asthma. The anti-**angiogenic**, anti-proliferative  
estradiol metabolite, 2-methoxyestradiol, is a candidate prophylactic

anti-asthma agent that may more specifically target the airway wall remodelling process.

IT 362-07-2, 2-Methoxyestradiol

RL: BAC (Biological activity or effector, except adverse); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)

(estradiol metabolites effects on airway remodelling in relation to asthma)

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 5 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:310080 HCAPLUS

DN 135:116756

TI The **antiangiogenic** property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors

AU Sweeney, Christopher J.; Miller, Kathy D.; Sissons, Sean E.; Nozaki, Shinichi; Heilman, Douglas K.; Shen, Jianzhao; Sledge, George W., Jr.

CS Department of Medicine, Indiana University, Indianapolis, IN, 46202, USA

SO Cancer Res. (2001), 61(8), 3369-3372

CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

AB Numerous chemotherapeutic agents have been shown to have an inhibitory effect on endothelial cell proliferation and migration, and tubule formation. In this study, we examd. the **antiangiogenic** activity of docetaxel. Docetaxel inhibited endothelial cell proliferation and tubule formation in vitro in a dose-dependent fashion. Docetaxel treatment also inhibited **angiogenesis** in an in vivo Matrigel plug assay. The endothelial stimulating factors, vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor are able to protect endothelial cells from the **antiangiogenic** properties of docetaxel. This protective effect can be overcome by a recombinant humanized monoclonal antibody directed against VEGF in both in vitro and in vivo models. Similarly, combination of docetaxel with the **antiangiogenic** agent 2-methoxyestradiol also overcomes the protective effect of VEGF in both in vitro and in vivo models. These data suggest that microenvironmental factors (e.g., local release of VEGF and basic fibroblast growth factor) could play a role in decreasing the **antiangiogenic** effects of docetaxel, whereas agents such as 2-methoxyestradiol and recombinant humanized monoclonal antibody directed against VEGF may reverse this protective effect.

IT 362-07-2, 2-Methoxyestradiol

RL: BAC (Biological activity or effector, except adverse); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)

(**antiangiogenic** property of docetaxel is synergistic with a humanized MAb against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors)

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 6 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:43056 HCAPLUS

DN 135:71332

TI 2-Methoxyestradiol: an endogenous **antiangiogenic** and antiproliferative drug candidate

AU Pribluda, Victor S.; Gubish, Edward R., Jr.; LaVallee, Theresa M.;

Treston, Anthony; Swartz, Glenn M.; Green, Shawn J.

CS EntreMed Inc., Rockville, MD, USA

SO Cancer Metastasis Rev. (2000), 19(1/2), 173-179

CODEN: CMRED4; ISSN: 0167-7659

PB Kluwer Academic Publishers

DT Journal; General Review

LA English

AB A review, with 43 refs. 2-Methoxyestradiol (2ME2), once considered an inactive end-metabolite of estradiol, has recently emerged as a very promising agent for cancer treatment. It is orally active in a wide range of tumor models, and inhibits tumor growth at doses showing no clin. signs of toxicity. 2ME2 targets both the tumor cell and endothelial cell compartments by inducing apoptosis in rapidly proliferating cells and inhibiting blood vessel formation at several stages in the **angiogenic** cascade. Moreover, the ability of 2ME2 to inhibit metastatic spread in several models adds to its therapeutic value for cancer treatment at various stages of the disease. Though the mechanism of action is still undefined, several potential mol. targets and pathways of activation have been suggested.

IT 362-07-2, 2-Methoxyestradiol

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(methoxyestradiol as endogenous **antiangiogenic** and antiproliferative drug candidate)

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 7 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:595071 HCAPLUS

DN 133:305736

TI 2-Methoxyestradiol blocks **estrogen**-induced rat pituitary tumor growth and tumor **angiogenesis**: possible role of vascular endothelial growth factor

AU Banerjee, Sushanta K.; Zoubine, Mikhail N.; Sarkar, Dipak K.; Weston, Allan P.; Shah, Jamshed H.; Campbell, Donald R.

CS Department of Medicine, University of Kansas Medical Center, Kansas City, KS, USA

SO Anticancer Res. (2000), 20(4), 2641-2645

CODEN: ANTRD4; ISSN: 0250-7005

PB International Institute of Anticancer Research

DT Journal

LA English

AB Natural and synthetic **estrogens** have been assocd. with several types of human and animal cancers including prolactin-secreting pituitary tumors in Fischer 344 rats. These prolactin-secreting tumors are highly **angiogenic** and their growth is **angiogenic** dependent. In the present study we have utilized this model to evaluate the effect of 2-methoxyestradiol (2-ME), an endogenous **estrogen** metabolite that is a potent inhibitor of endothelial cell proliferation in vitro, on **estrogen**-induced pituitary tumor growth and **angiogenesis**. Adult female rats were implanted (s.c.) with a silastic capsule contg. estradiol-17.beta. (E2). After seven days of const. E2 exposure animals were injected (s.c.) daily with 25 mg/kg of 2-ME and killed either three or 8 days later. Changes in pituitary wt. and proliferating cell nuclear antigen (PCNA) labeling index indicated growth while degree of **angiogenesis** was detd. immunohistochem. using factor VIII related antigen. The results indicate that 2-ME inhibited **estrogen**-induced lactotroph growth by 32% and tumor **angiogenesis** by 89%. Furthermore, vascular endothelial growth factor (VEGF) expression, evaluated by immunohistochem. anal., was down-regulated concomitant with tumor **angiogenic** suppression. These studies suggest that 2-ME may have therapeutic potential for hormone-induced cancer and that its **angiostatic** activity may be modulated through down-regulation of VEGF expression.

IT 362-07-2, 2-Methoxyestradiol

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(methoxyestradiol blocks **estrogen**-induced rat pituitary tumor growth and tumor **angiogenesis** and VEGF role therein)

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 8 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:592560 HCAPLUS  
 DN 133:198575  
 TI Compositions and methods for use in targeting vascular destruction  
 IN Pero, Ronald W.; Sherris, David  
 PA Oxigene, Inc., USA  
 SO PCT Int. Appl., 36 pp.  
 CODEN: PIXXD2

DT **Patent**  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000048606	A1	20000824	WO 2000-US3996	20000216
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1152764	A1	20011114	EP 2000-914606	20000216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1999-120478	P	19990218		
	WO 2000-US3996	W	20000216		
OS	MARPAT 133:198575				
AB	Treatment of warm-blooded animals having a tumor or non-malignant hypervascularization, by administering a sufficient amt. of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel phosphatases, so that microvessels are destroyed preferentially over other normal tissues, because the less cytotoxic prodrug form is converted to the highly cytotoxic dephosphorylated form.				
IT	<b>362-07-2, 2-Methoxyestradiol</b> RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); <b>THU (Therapeutic use)</b> ; BIOL (Biological study); PROC (Process); USES (Uses) (prodrugs for use in targeting vascular destruction)				
RE.CNT	1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L71 ANSWER 9 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:261865 HCAPLUS  
 DN 133:14181

TI Enhancement of radiation effects in vitro by the **estrogen**  
 metabolite 2-methoxyestradiol

AU Amorino, George P.; Freeman, Michael L.; Choy, Hak  
 CS Department of Radiation Oncology, Vanderbilt University Medical Center,  
 Nashville, TN, 37232, USA

SO Radiat. Res. (2000), 153(4), 384-391  
 CODEN: RAREAE; ISSN: 0033-7587

PB Radiation Research Society

DT Journal

LA English

AB 2-Methoxyestradiol (2-ME) is an endogenous estradiol metabolite that  
 disrupts microtubule function, suppresses murine tumors, and inhibits  
**angiogenesis**. Since some microtubule inhibitors have been shown  
 to alter radiosensitivity, we have evaluated 2-ME as a radiation enhancer  
 in vitro. H460 human lung cancer cells were plated, treated with 2-ME for  
 24 h, and irradiated; then colony-forming ability was assessed. The  
 radiation dose enhancement ratios (DERs) using this protocol were 1.3, 1.8  
 and 2.1 for 1, 1.5 and 2 .mu.M 2-ME, resp. Using a single-cell plating  
 protocol, the resp. DERs were 1.2, 1.5 and 1.8. The parent compd. of  
 2-ME, .beta.-estradiol, did not enhance radiation effects at equally

cytotoxic doses. Isobologram anal. showed that 1 .mu.M 2-ME was additive with radiation, but that 1.5 and 2 .mu.M were synergistic. Cell cycle anal. showed a dose-dependent increase in the percentage of cells in the radiosensitive G2/M phase after a 24-h treatment with 2-ME; a threefold increase in the percentage of cells in G2/M phase was obsd. using 2 .mu.M 2-ME. Treatment with 2 .mu.M 2-ME almost completely inhibited repair of sublethal damage (SLD) as shown using split-dose recovery. Radiosensitive, repair-deficient murine SCID (severe combined immunodeficient) cells did not show enhancement of radiation effects with 2 .mu.M 2-ME, but enhancement was obsd. in the wild-type parental cells (CB-17). SCID cells complemented with human DNA-dependent protein kinase restored radioenhancement by 2-ME. In addn., MCF-7 breast cancer cells were also radiosensitized by 2 .mu.M 2-ME (DER = 2.1). These data suggest that 2-ME is a potential radiation sensitizer, in addn. to its previously reported antitumor and **antiangiogenic** properties. We have verified the **antiangiogenic** activity of 2-ME in vitro using human endothelial cells. Based on these results, we hypothesize that the mechanism of radiation enhancement may involve redistribution of cells into G2/M phase by 2-ME, and that the resulting population of cells is repair-deficient and thus radiosensitive.

IT 362-07-2, 2-Methoxyestradiol

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (estrogen metabolite 2-methoxyestradiol enhancement of radiation effects)

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 10 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:227537 HCAPLUS

DN 132:262172

TI Use of **neoangiogenesis** markers for diagnosis and treatment of tumors

IN Krause, Werner; Muschick, Peter

PA Schering Aktiengesellschaft, Germany

SO PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000018439	A2	20000406	WO 1999-EP7198	19990929
	WO 2000018439	A3	20000914		
	W:	AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, ES, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
	DE 19845798	A1	20000413	DE 1998-19845798	19980929

PRAI DE 1998-19845798 A 19980929

AB **Neoangiogenesis** markers (i.e. antibodies or receptors for e.g. vascular endothelial growth factor, placenta growth factor, acidic or basic FGF, transforming growth factor .alpha. or .beta., hepatocyte growth factor, insulin-like growth factor I, glycoprotein B61, protein LERK-1, flk-1 receptor, etc.) or partial sequences thereof and **antiangiogenic** compds. and factors such as paclitaxel, endostatin, fibronectin peptide, and fumagillin are conjugated with active agents such as chemotherapeutic agents, radiosensitizers, photosensitizers, antibodies, oligonucleotides, radioactive metal complexes, etc., which may be bound to carriers, for treatment of tumors. Likewise, **neoangiogenesis** markers may be conjugated to diagnostic agents such as MRI, radiog., ultrasound, or near-IR contrast agents for tumor diagnosis. Thus, N',N',N''',N''''-tetrakis(tert-butoxycarboxymethyl)-N'''-

(hydroxycarboxymethyl)diethylenetriamine was converted to its N-hydroxysuccinimide ester, coupled to a Thy-1 antibody, complexed with <sup>186</sup>Re, and injected i.v. into rabbits for detection of implanted VX2 tumors by scintigraphy with a gamma camera.

IT 362-07-2

RL: ARG (Analytical reagent use); BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)

(**angiogenesis** marker; use of **neoangiogenesis** markers for diagnosis and treatment of tumors)

L71 ANSWER 11 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:144722 HCAPLUS

DN 132:185454

TI Use of anti-**angiogenic** agents for inhibiting vessel wall injury

IN Brown, Charles L., III; Gorlin, Steve

PA Global Vascular Concepts, Inc., USA

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT **Patent**

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000010552	A2	20000302	WO 1999-US19218	19990824
	WO 2000010552	A3	20001123		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9956871	A1	20000314	AU 1999-56871	19990824
PRAI	US 1998-97579	P	19980824		
	WO 1999-US19218	W	19990824		

AB Use of anti-**angiogenic** agents to inhibit an undesirable response to vessel wall injury, including stent neointima, dialysis graft neointima, vascular graft-induced neointima, and the treatment of benign hypertrophic scar formation as well as the treatment and passivation of unstable atherosclerotic plaques are provided. The invention provides for the use of catheter-based devices for enhancing the local delivery of anti-**angiogenic** agents into the endothelial tissues of blood vessels of the living body.

IT 362-07-2, 2-Methoxyestradiol

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)  
(anti-**angiogenic** agents for inhibiting vessel wall injury)

L71 ANSWER 12 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:736476 HCAPLUS

DN 131:346535

TI Use of neomycin for treating **angiogenesis**-related diseases

IN Hu, Guo-Fu; Vallee, Bert L.

PA The Endowment for Research In Human Biology, Inc., USA

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DT **Patent**

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958126	A1	19991118	WO 1999-US10269	19990511
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,			



JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,  
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,  
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,  
MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9939804 A1 19991129 AU 1999-39804 19990511

EP 1083896 A1 20010321 EP 1999-922915 19990511

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

PRAI US 1998-84921 P 19980511

WO 1999-US10269 W 19990511

AB The present invention is directed to using neomycin or an analog thereof as a therapeutic agent to treat **angiogenesis**-related diseases, which are characterized by excessive, undesired or inappropriate **angiogenesis** or proliferation of endothelial cells. The present invention is also directed to pharmaceutical compns. comprising: (a) neomycin or an analog and, optionally, (b) another anti-**angiogenic** agent or an anti-neoplastic agent. The present invention is further directed to a method for screening neomycin analogs having anti-**angiogenic** activity. A preferred embodiment of the invention relates to using neomycin to treat subjects having such diseases. A dose of 20 ng neomycin/embryo or higher completely inhibited **angiogenin**-induced **angiogenesis** in the chorioallantoic membrane (CAM) assay. Neomycin inhibits **angiogenin**-induced **angiogenesis** mainly through inhibition of nuclear translocation of **angiogenin**.

IT 362-07-2, 2-Methoxyestradiol

RL: BAC (Biological activity or effector, except adverse); THU  
(**Therapeutic use**); BIOL (Biological study); USES (Uses)  
(neomycin, its analogs and other agents for treatment of  
**angiogenesis**-related diseases)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 13 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:672339 HCAPLUS

DN 132:520

TI **Angiostatic** activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization

AU McNatt, Loretta G.; Weimer, Lori; Yanni, John; Clark, Abbot F.

CS Alcon Laboratories, Inc., Fort Worth, TX, USA

SO J. Ocul. Pharmacol. Ther. (1999), 15(5), 413-423

CODEN: JOPTFU; ISSN: 1080-7683

PB Mary Ann Liebert, Inc.

DT Journal

LA English

AB Ocular neovascular diseases represent a major cause of blindness in the world. **Angiostatic** steroids are a unique class of compds. which inhibit the formation of new blood vessels in various models, including ocular models of **angiogenesis**. In search of potent new anti-**angiogenic** agents for the treatment of ocular neovascular disease, a large group of steroids were evaluated for **angiostatic** activity in the chick embryo CAM model. **Angiostatic** activity was found among all steroid classes included in the study. There was a good correlation between the **angiostatic** efficacies of 15 diverse steroids tested in the chick CAM and in the rabbit LPS-induced corneal pocket models of neovascularization ( $r=0.76$ ,  $p=0.01$ ). These studies show that potent **angiostatic** steroids inhibit neovascularization in two different animal models, suggesting a common mechanism of action. Glucocorticoid therapy is sometimes assocd. with ocular side effects. Two of the most potent **angiostatic** steroids, AL-3789 and AL-4940, were evaluated for glucocorticoid-mediated anti-inflammatory activity in the in vitro U937 cell model of LPS-induced IL-1 induction and found to be devoid of glucocorticoid activity.

**Angiostatic** steroids which lack glucocorticoid activity should be attractive drug candidates for treating ocular neovascular disease.

IT 362-07-2, 2-Methoxyestradiol

RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**angiostatic** activity of steroids in chick embryo CAM and rabbit cornea models of neovascularization)

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:48631 HCAPLUS

DN 130:119599

TI Pharmaceutical compositions comprising an **angiostatic** steroid combined with a hyaluronan for increasing neovascularization and **angiogenesis** during wound healing

IN Seed, Michael P.; Alam, Chandan; Willoughby, Derek A.

PA Hyal Pharmaceutical Corporation, Can.

SO PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9901142	A1	19990114	WO 1998-CA649	19980703
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2208916	AA	19990103	CA 1997-2208916	19970703
	AU 9882021	A1	19990125	AU 1998-82021	19980703
PRAI	CA 1997-2208916		19970703		
	WO 1998-CA649		19980703		
AB	A pharmaceutical compn. is disclosed for increasing neovascularization and <b>angiogenesis</b> during wound healing in a mammal beyond the level of neovascularization and <b>angiogenesis</b> which would occur at the wound site without any treatment, the compn. comprising an effective amt. of any <b>angiostatic</b> steroid which has reduced or no deteriorative or detrimental side effects, combined with an effective amt. of a form of hyaluronan, e.g. hyaluronic acid or a pharmaceutically acceptable salt thereof.				

IT 362-07-2 362-08-3

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**angiostatic** steroid-hyaluronan combination for increasing neovascularization and **angiogenesis** during wound healing)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 15 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 1998:785662 HCAPLUS

DN 130:33040

TI Methods using 7-(substituted amino)-9-[(substituted glycyloamido]-6-demethyl-6-deoxytetracyclines for inhibiting **angiogenesis**, proliferation of endothelial or tumor cells, and tumor growth

IN Backer, Joseph M.; Bohlen, Peter

PA American Cyanamid Company, USA

SO U.S., 12 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5843925	A	19981201	US 1994-354694	19941213
	US 5856315	A	19990105	US 1998-84484	19980526
PRAI	US 1994-354694		19941213		

OS MARPAT 130:33040

AB A method is provided for inhibiting **angiogenesis** and proliferation of endothelial cells by administering an inhibitory amt. of a 7-(substituted amino)-9-[(substituted glycy)amido]-6-demethyl-6-deoxytetracycline (Markush included). Also provided is a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amt. of a compd. of the invention in combination with a chemotherapeutic agent or radiation therapy. Further provided are compns. contg. an effective inhibitory amt. of a compd. of the invention in a pharmaceutically acceptable carrier.

IT 362-07-2, 2-Methoxyestradiol

RL: BAC (Biological activity or effector, except adverse); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)

(deoxytetracycline prepn. for inhibiting **angiogenesis**, proliferation of endothelial or tumor cells, and tumor growth, and compns. with other agents)

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 16 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 1998:778968 HCAPLUS

DN 130:105451

TI Inhibition of normal and experimental **angiotumor** endothelial cell proliferation and cell cycle progression by 2-methoxyestradiol

AU Reiser, F.; Way, D.; Bernas, M.; Witte, M.; Witte, C.

CS Department of Surgery, The University of Arizona, Tucson, AZ, 85724, USA

SO Proc. Soc. Exp. Biol. Med. (1998), 219(3), 211-216

CODEN: PSEBAA; ISSN: 0037-9727

PB Blackwell Science, Inc.

DT Journal

LA English

AB With rapid growth and metab., aggressive cancers require an extensive vascular network, termed tumor **angiogenesis**. The body produces a variety of natural **angiogenic** inhibitors, among which is the mammalian **estrogen** metabolite, 2-methoxyestradiol (2-MeOE2). In this study, we compared the effects of 2-MeOE2 on a human umbilical vein cell line (HUVEC-C) and on an immortal, **angiotumor**-producing rat sinusoidal endothelial cell line (RSE-1). In vitro, the effects of varying concns. of 2-MeOE2 from 0.01-100.0 .mu.M were measured with cell counts and compared to control cells. HUVEC-C had an ED50 .apprx.3.5 .mu.M with .apprx.27% inhibition of cell growth whereas RSE-1 had an ED50 .apprx.2.2 .mu.M with .apprx.50% inhibition of cell growth compared with controls. The lowest concn. with maximal effect was 10.0 .mu.M 2-MeOE2 for both cell lines. Using this concn., flow cytometric anal. of cell cycles was performed with propidium iodide stained DNA of HUVEC-C and RSE-1 at 24 and 48 h. Both demonstrated a significant block at G2M of the cell cycle. At 48 h, HUVEC-C had 32% of cells in G2M (control = 9% G2M), and RSE-1 had 36% of cells in G2M (control = 18% G2M). These findings demonstrate a strong in vitro antiproliferative effect of 2-MeOE2 on normal dividing endothelial as well as **angiotumor** cells mediated through a cell cycle-specific block at G2M. The antiendothelial, **antiangiotumor** effect of 2-MeOE2 supports its potential as a therapeutic agent against solid organ cancers, benign or malignant vascular growths, and other pathol. states dependent on **angiogenesis**.

IT 362-07-2, 2-Methoxyestradiol

RL: BAC (Biological activity or effector, except adverse); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)

(methoxyestradiol inhibition of normal and exptl. **angiotumor**)

endothelial cell proliferation and cell cycle progression)  
 RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 17 OF 22 HCAPLUS COPYRIGHT 2002 ACS  
 AN 1998:369884 HCAPLUS  
 DN 129:90490  
 TI Is 2-methoxyestradiol an endogenous **estrogen** metabolite that inhibits mammary carcinogenesis?  
 AU Zhu, Bao Ting; Conney, Allan H.  
 CS Laboratory for Cancer Research, Department of Chemical Biology, College of Pharmacy, Rutgers-The State University of New Jersey, Piscataway, NJ, 08854-8020, USA  
 SO Cancer Res. (1998), 58(11), 2269-2277  
 CODEN: CNREA8; ISSN: 0008-5472  
 PB American Association for Cancer Research  
 DT Journal; General Review  
 LA English  
 AB A review, with 172 refs. Catechol **estrogens** (2- or 4-hydroxyestradiol and 2- or 4-hydroxyestrone) are chem. reactive **estrogen** metabolites that are O-methylated to less polar monomethyl ethers by catechol-O-methyltransferase, an enzyme present in many tissues such as the liver, kidney, brain, placenta, uterus, and mammary gland. In the present report, the authors review recent studies on the antitumorigenic and **antiangiogenic** effects of exogenously administered 2-methoxyestradiol in vitro and in vivo. The authors also discuss data that suggest that endogenous formation of 2-methoxyestradiol (and its 2-hydroxyestradiol precursor) may have a protective effect on **estrogen**-induced cancers in target organs. Although the mol. mechanism of action of 2-methoxyestradiol is not clear, the authors suggest that some unique effects of 2-methoxyestradiol may be mediated by a specific intracellular effector or receptor that is refractory to the parent hormone, estradiol. Addnl. research is needed to identify factors that regulate the metabolic formation and disposition of 2-methoxyestradiol in liver and in target cells and to evaluate the effects of modulating 2-methoxyestradiol formation on **estrogen**-induced carcinogenesis.  
 IT 362-07-2, 2-Methoxyestradiol  
 RL: BAC (Biological activity or effector, except adverse); MFM (Metabolic formation); **THU (Therapeutic use)**; BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)  
 (methoxyestradiol antitumorigenic and **antiangiogenic** effects in vitro and in vivo)

L71 ANSWER 18 OF 22 HCAPLUS COPYRIGHT 2002 ACS  
 AN 1997:752842 HCAPLUS  
 DN 128:30711  
 TI Treatment of asthma and airway diseases using steroids or steroid analogs  
 IN Stewart, Alastair George  
 PA Amrad Operations Pty. Ltd., Australia; Stewart, Alastair George  
 SO PCT Int. Appl., 63 pp.  
 CODEN: PIXXD2  
 DT **Patent**  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9742958	A1	19971120	WO 1997-AU286	19970509
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

AU 9726276 A1 19971205 AU 1997-26276 19970509  
 AU 725048 B2 20001005  
 CN 1218401 A 19990602 CN 1997-194505 19970509  
 EP 923376 A1 19990623 EP 1997-917945 19970509

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, FI

US 5962445 A 19991005 US 1997-853528 19970509  
 JP 2000507923 T2 20000627 JP 1997-530434 19970509  
 US 6200966 B1 20010313 US 1999-330918 19990611

PRAI AU 1996-9766 A 19960509  
 AU 1996-9918 A 19960520  
 US 1997-853528 A1 19970509  
 WO 1997-AU286 W 19970509

AB The invention relates to use of steroids or steroid analogs in the treatment of chronic and acute inflammation of the airways, particularly asthmatic conditions. It also relates to compds. and compns. which modulate airway remodelling. In a preferred embodiment, the active component inhibits inflammation and smooth muscle cell proliferation in the airway wall. It may also have a least one other activity selected from **antiangiogenesis**, antioxidn., and the ability to disrupt microtubule formation. In a preferred embodiment, the steroid is 2-methoxyoestradiol.

IT **362-07-2**, 2-Methoxyestradiol **362-08-3**, 2-Methoxyestrone  
 RL: BAC (Biological activity or effector, except adverse); **THU**  
**(Therapeutic use)**; BIOL (Biological study); USES (Uses)  
 (treatment of asthma and airway diseases using steroids or steroid analogs)

L71 ANSWER 19 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 1997:483454 HCAPLUS

DN 127:91017

TI Method and composition for treatment of pathological conditions associated with **angiogenesis**

IN Fotsis, Theodore; Adlercreutz, Herman; Schweigerer, Lothar

PA Germany

SO U.S., 10 pp. Cont.-in-part of U.S. Ser. No. 84,969, abandoned.

CODEN: USXXAM

DT **Patent**

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5643900	A	19970701	US 1995-405776	19950317

PRAI US 1993-84969 19930702

AB The present invention relates to a method and a compn. for the treatment of pathol. conditions assocd. with enhanced **angiogenesis**. The method comprises administering 2-methoxyestradiol to a subject in need of such treatment. 2-Methoxyestradiol also has potent pharmacol. properties in the treatment of solid tumors.

IT **362-07-2**, 2-Methoxyestradiol  
 RL: BAC (Biological activity or effector, except adverse); **THU**  
**(Therapeutic use)**; BIOL (Biological study); USES (Uses)  
 (treatment of **angiogenic** diseases and solid tumors with 2-methoxyestradiol)

L71 ANSWER 20 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 1997:84466 HCAPLUS

DN 126:140011

TI Suppression of type II collagen-induced arthritis by the endogenous **estrogen** metabolite 2-methoxyestradiol

AU Josefsson, Elisabet; Tarkowski, Andrej

CS University of Goteborg, Goteborg, Swed.

SO Arthritis Rheum. (1997), 40(1), 154-163

CODEN: ARHEAW; ISSN: 0004-3591

PB Lippincott-Raven

DT Journal

LA English

AB To evaluate the antiarthritic properties of 2-methoxyestradiol, an endogenous metabolite of estradiol, on type II collagen-induced arthritis (CIA) in DBA/1 mice, the effects of treatment with 2-methoxyestradiol on the development of CIA were evaluated clin. and histol. The in vitro effects of 2-methoxyestradiol on lymphocyte and endothelial cell proliferation and differentiation were analyzed by std. methods. The development of CIA was significantly suppressed by 2-methoxyestradiol. Incubation with 2-methoxyestradiol suppressed the in vitro proliferation of endothelial cells, indicating that this compd. down-regulates **angiogenesis**. Endothelial cell prodn. of nitric oxide (NO) was also down-regulated by 2-methoxyestradiol. In contrast to estradiol, 2-methoxyestradiol exerted neither detectable feminizing effects on the sex organs nor inhibition of leukocyte development in hematopoietic organs. The development of CIA is suppressed by 2-methoxyestradiol, possibly via inhibition of **angiogenesis**. Diminished NO prodn. could be of importance in vivo because it is a potent pro-inflammatory mediator. Since 2-methoxyestradiol exerts only mild side effects compared with estradiol, it is an interesting candidate for therapeutic use in inflammatory diseases.

IT 362-07-2, 2-Methoxyestradiol

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(suppression of type II collagen-induced arthritis by endogenous **estrogen** metabolite 2-methoxyestradiol)

L71 ANSWER 21 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 1997:39755 HCAPLUS

DN 126:127078

TI Inhibition of **angiogenesis** and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol

AU Klauber, Nancy; Parangi, Sareh; Flynn, Evelyn; Hamel, Ernest; D'Amato, Robert J.

CS Department Surgery, Children's Hospital and Harvard Medical School, Boston, MA, 02115, USA

SO Cancer Res. (1997), 57(1), 81-86  
CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

AB 2-Methoxyestradiol (2-ME), an endogenous **estrogen** metabolite which disrupts microtubule function, has been shown to inhibit proliferating cells in vitro and suppress certain murine tumors in vivo. In vitro screening has detd. that breast cancer cell lines are most sensitive to inhibition by 2-ME. Addnl., 2-ME has been shown to inhibit **angiogenesis** in vitro. We tested whether 2-ME suppresses cytokine-induced **angiogenesis** in vivo and inhibits growth of a human breast carcinoma in severe combined immunodeficient mice. A model of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF)-induced corneal neovascularization in C57BL/6 mice was used to evaluate the **antiangiogenic** effects of 2-ME and other microtubule inhibitors such as Taxol, vincristine, and colchicine. 2-ME (150 mg/kg p.o.) inhibited bFGF and VEGF-induced neovascularization by 39% and 54%, resp. Taxol (6 mg/kg i.p.) inhibited bFGF and VEGF-induced neovascularization by 45% and 37%, resp. Vincristine (0.2 mg/kg i.p.) and colchicine (0.25 mg/kg i.p.) had no effect. Treatment with 2-ME (75 mg/kg p.o.) for 1 mo suppressed the growth of a human breast carcinoma in mice by 60% without toxicity. Recognition of the **antiangiogenic** and antitumor properties of 2-ME and taxol may be crucial in planning clin. applications to **angiogenesis**-dependent diseases.

IT 362-07-2, 2-Methoxyestradiol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(inhibition of **angiogenesis** and breast cancer in mice by microtubule inhibitors methoxyestradiol and taxol)

L71 ANSWER 22 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 1996:640895 HCAPLUS  
DN 125:292016  
TI Inhibitors of **angiogenesis** in human urine  
AU Fotsis, Theodore; Pepper, Michael S.; Aktas, Erkan; Joussen, Antonia;  
Kruse, Friedrich; Adelcreutz, Herman; Waehaelea, Kristina; Hase, Tapio;  
Montesano, Roberto; Schweigerer, Lothar  
CS Children's University Hospital, University of Heidelberg, Heidelberg,  
69120, Germany  
SO NATO ASI Ser., Ser. A (1996), 285 (Molecular, Cellular, and Clinical  
Aspects of Angiogenesis), 213-227  
CODEN: NALSDJ; ISSN: 0258-1213  
DT Journal; General Review  
LA English  
AB A review with .apprx.50 refs. on the authors' work in screening urine of  
human subjects consuming a diet rich in plant products for anti-  
**angiogenic** compds. The authors identified the isoflavonoid  
genistein, the endogenous **estrogen** metabolite 2-methoxyestradiol  
and metabolites of flavonoids that show inhibitory activities against  
**angiogenesis**. Irresp. of whether or not these substances play any  
physiol. role in humans, they might be suitable as pharmacol. agents for  
treatment of solid malignant tumors and other **angiogenic**  
diseases.  
IT 362-07-2, 2-Methoxyestradiol  
RL: BAC (Biological activity or effector, except adverse); BOC (Biological  
occurrence); THU (**Therapeutic use**); BIOL (Biological study);  
OCCU (Occurrence); USES (Uses)  
(inhibitors of **angiogenesis** isolated from human urine in  
relation to antitumor activity and treatment of **angiogenic**  
diseases)

=> fil reg

FILE 'REGISTRY' ENTERED AT 15:30:07 ON 19 FEB 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 18 FEB 2002 HIGHEST RN 393508-26-4  
DICTIONARY FILE UPDATES: 18 FEB 2002 HIGHEST RN 393508-26-4

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES  
for more information. See STN Note 27, Searching Properties in the CAS  
Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

The P indicator for Preparations was not generated for all of the  
CAS Registry Numbers that were added to the H/Z/CA/CAplus files between  
12/27/01 and 1/23/02. Use of the P indicator in online and SDI searches  
during this period, either directly appended to a CAS Registry Number  
or by qualifying an L-number with /P, may have yielded incomplete results.  
As of 1/23/02, the situation has been resolved. Also, note that searches  
conducted using the PREP role indicator were not affected.

Customers running searches and/or SDIs in the H/Z/CA/CAplus files  
incorporating CAS Registry Numbers with the P indicator between 12/27/01  
and 1/23/02, are encouraged to re-run these strategies. Contact the  
CAS Help Desk at 1-800-848-6533 in North America or 1-614-447-3698,  
worldwide, or send an e-mail to [help@cas.org](mailto:help@cas.org) for further assistance or to  
receive a credit for any duplicate searches.


=> d ide can tot 169

L69 ANSWER 1 OF 16 REGISTRY COPYRIGHT 2002 ACS  
 RN 383414-35-5 REGISTRY  
 CN Estra-1,3,5(10)-triene-3,17-diol, 2-(2,2,2-trifluoroethyl)-, (17.beta.)-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN NSC 678473  
 FS STEREOSEARCH  
 MF C20 H25 F3 O2  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.



*remaining hit  
 compounds from  
 references*

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 136:64669

L69 ANSWER 2 OF 16 REGISTRY COPYRIGHT 2002 ACS  
 RN 302799-37-7 REGISTRY  
 CN Estra-1,3,5(10)-triene-3,6,17-triol, 2-ethoxy-, (17.beta.)-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN NSC 683688  
 FS STEREOSEARCH  
 MF C20 H28 O4  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*



2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

REFERENCE 2: 133:322044

L69 ANSWER 3 OF 16 REGISTRY COPYRIGHT 2002 ACS

RN 192062-20-7 REGISTRY

CN Estra-1,3,5(10)-trien-6-one, 2-ethoxy-3,17-dihydroxy-, O-methyloxime,  
(17.beta.)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN NSC 683125

FS STEREOSEARCH


MF C21 H29 N O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.

Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1967 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

REFERENCE 2: 133:322044

REFERENCE 3: 127:95444

L69 ANSWER 4 OF 16 REGISTRY COPYRIGHT 2002 ACS

RN 192062-15-0 REGISTRY

CN Estra-1,3,5(10)-trien-6-one, 3,17-dihydroxy-2-(2,2,2-trifluoroethoxy)-,  
oxime, (17.beta.)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN NSC 681683

FS STEREOSEARCH


MF C20 H24 F3 N O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.

Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1967 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

REFERENCE 2: 133:322044

REFERENCE 3: 127:95444

L69 ANSWER 5 OF 16 REGISTRY COPYRIGHT 2002 ACS

RN 192062-14-9 REGISTRY

CN Estra-1,3,5(10)-trien-6-one, 2-ethoxy-3,17-dihydroxy-, oxime, (17.beta.)-  
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN NSC 680185

FS STEREOSEARCH


MF C20 H27 N O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.

Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1967 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

REFERENCE 2: 133:322044

REFERENCE 3: 127:95444

L69 ANSWER 6 OF 16 REGISTRY COPYRIGHT 2002 ACS

RN 192062-13-8 REGISTRY

CN Estra-1,3,5(10)-trien-6-one, 3,17-dihydroxy-2-(2,2,2-trifluoroethoxy)-,  
(17.beta.)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN NSC 681684


FS STEREOSEARCH

MF C20 H23 F3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1967 TO DATE)

3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

REFERENCE 2: 133:322044

REFERENCE 3: 127:95444

L69 ANSWER 7 OF 16 REGISTRY COPYRIGHT 2002 ACS

RN 192062-12-7 REGISTRY

CN Estra-1,3,5(10)-trien-6-one, 2-ethoxy-3,17-dihydroxy-, (17.beta.)- (9CI)  
(CA INDEX NAME)

OTHER NAMES:

CN NSC 679431


FS STEREOSEARCH

MF C20 H26 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

6 REFERENCES IN FILE CA (1967 TO DATE)

6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

REFERENCE 2: 134:326663

REFERENCE 3: 133:322044

REFERENCE 4: 133:105195

REFERENCE 5: 132:303593

REFERENCE 6: 127:95444

L69 ANSWER 8 OF 16 REGISTRY COPYRIGHT 2002 ACS

RN 192062-02-5 REGISTRY

CN Estra-1,3,5(10)-triene-3,17-diol, 2-(1-propynyl)-, (17.beta.)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN NSC 682429


FS STEREOSEARCH

MF C21 H26 O2

SR CA

LC .STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

REFERENCE 2: 127:95444

L69 ANSWER 9 OF 16 REGISTRY COPYRIGHT 2002 ACS

RN 165619-13-6 REGISTRY

CN Estra-1,3,5(10)-triene-3,17-diol, 2-(1-pentenyl)-, [2(E),17.beta.]- (9CI)  
(CA INDEX NAME)

FS STEREOSEARCH


MF C23 H32 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:112496

L69 ANSWER 10 OF 16 REGISTRY COPYRIGHT 2002 ACS

RN 165619-12-5 REGISTRY

CN Estra-1,3,5(10)-triene-3,17-diol, 2-(1-butenyl)-, [2(E),17.beta.]- (9CI)  
(CA INDEX NAME)

FS STEREOSEARCH


MF C22 H30 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:112496

L69 ANSWER 11 OF 16 REGISTRY COPYRIGHT 2002 ACS  
RN 165619-09-0 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(1-methylethoxy)-, (17.beta.)- (9CI)  
(CA INDEX NAME)  
FS STEREOSEARCH  
MF C21 H30 O3  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:112496

L69 ANSWER 12 OF 16 REGISTRY COPYRIGHT 2002 ACS  
RN 165619-08-9 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 2-propoxy-, (17.beta.)- (9CI) (CA INDEX  
NAME)  
FS STEREOSEARCH  
MF C21 H30 O3  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 123:112496

L69 ANSWER 13 OF 16 REGISTRY COPYRIGHT 2002 ACS  
RN 165619-07-8 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 2-ethoxy-, (17.beta.)- (9CI) (CA INDEX  
NAME)

## OTHER NAMES:

CN 2-Ethoxyestradiol  
 CN NSC 671043  
 FS STEREOSEARCH  
 MF C20 H28 O3  
 SR CA  
 LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry. Rotation (+).



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

- 7 REFERENCES IN FILE CA (1967 TO-DATE)
- 7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669  
 REFERENCE 2: 134:326663  
 REFERENCE 3: 133:322044  
 REFERENCE 4: 132:303593  
 REFERENCE 5: 129:245330  
 REFERENCE 6: 127:95444  
 REFERENCE 7: 123:112496

L69 ANSWER 14 OF 16 REGISTRY COPYRIGHT 2002 ACS

RN 22415-44-7 REGISTRY

CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 2-methoxy-, (17.alpha.)-(9CI) (CA INDEX NAME)

## OTHER CA INDEX NAMES:

CN 19-Nor-17.alpha.-pregna-1,3,5(10)-trien-20-yne-3,17-diol, 2-methoxy- (8CI)

## OTHER NAMES:

CN 17.alpha.-Ethinyl-2-methoxyestradiol

CN 2-Methoxy-17.alpha.-ethynylestradiol

FS STEREOSEARCH


DR 26011-46-1

MF C21 H26 O3

LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT, MEDLINE, TOXCENTER, TOXLIT, USPATFULL

(\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

21 REFERENCES IN FILE CA (1967 TO DATE)

4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

21 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669  
 REFERENCE 2: 132:132481  
 REFERENCE 3: 122:256433  
 REFERENCE 4: 118:161228  
 REFERENCE 5: 108:94834  
 REFERENCE 6: 104:1000  
 REFERENCE 7: 102:106508  
 REFERENCE 8: 101:48797  
 REFERENCE 9: 100:185989  
 REFERENCE 10: 100:17962

L69 ANSWER 15 OF 16 REGISTRY COPYRIGHT 2002 ACS

RN 362-08-3 REGISTRY

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-methoxy- (8CI, 9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Estrone, 2-methoxy- (6CI)

OTHER NAMES:

CN 2-Hydroxyestrone 2-methyl ether

CN 2-Methoxyestrone

FS STEREOSEARCH

MF C19 H24 O3

LC STN Files: ANABSTR, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, MEDLINE, SPECINFO, TOXCENTER, TOXLIT, USPATFULL


(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

257 REFERENCES IN FILE CA (1967 TO DATE)  
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 257 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 34 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:79753  
 REFERENCE 2: 136:64669  
 REFERENCE 3: 136:31843  
 REFERENCE 4: 136:3843  
 REFERENCE 5: 135:366956  
 REFERENCE 6: 135:221459  
 REFERENCE 7: 135:195698  
 REFERENCE 8: 135:175599  
 REFERENCE 9: 135:147586  
 REFERENCE 10: 134:321936

L69 ANSWER 16 OF 16 REGISTRY COPYRIGHT 2002 ACS

RN 362-07-2 REGISTRY

CN Estradiol, 2-methoxy-, (17.beta.)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Estradiol, 2-methoxy-, (17.beta.)- (7CI, 8CI)

CN Estradiol, 2-methoxy- (6CI)

OTHER NAMES:

CN 2-Hydroxyestradiol 2-methyl ether

CN 2-Methoxyestradiol, 1,3,5(10)-triene-3,17.beta.-diol

CN 2-Methoxyestradiol

CN NSC 659853

FS STEREOSEARCH


MF C19 H26 O3

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*,  
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,  
 CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE,  
 IFICDB, IFIPAT, IFIUDB, MEDLINE, PROMT, RTECS\*, SPECINFO, TOXCENTER,  
 TOXLIT, USPATFULL

(\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

299 REFERENCES IN FILE CA (1967 TO DATE)  
 7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 300 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 24 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:112738  
 REFERENCE 2: 136:79991  
 REFERENCE 3: 136:79754  
 REFERENCE 4: 136:79753  
 REFERENCE 5: 136:64669  
 REFERENCE 6: 136:48639  
 REFERENCE 7: 136:42803  
 REFERENCE 8: 136:31870  
 REFERENCE 9: 136:31843  
 REFERENCE 10: 136:31835


=> s 130 not 168  
 L72 64 L30 NOT L68

=>  
 => d ide can tot

L72 ANSWER 1 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 345317-45-5 REGISTRY  
 CN Estra-1,3,5(10)-trien-17-ol, 2-(2-propenyl)-, (17.β.)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C21 H28 O  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXLIT

Absolute stereochemistry.

← remaining hits  
 from STN search



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:56201

L72 ANSWER 2 OF 64 REGISTRY COPYRIGHT 2002 ACS

RN 302799-36-6 REGISTRY

CN Estra-1,3,5(10)-trien-3-ol, 17-amino-2-ethoxy-, hydrochloride (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C20 H29 N O2 . Cl H

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



● HCl

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:322044

L72 ANSWER 3 OF 64 REGISTRY COPYRIGHT 2002 ACS

RN 300853-53-6 REGISTRY

CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, (8.alpha.,9.beta.,13.alpha.,14.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN ent-2-Methoxyestra-1,3,5(10)-triene-16.alpha.,17.beta.-diol


FS STEREOSEARCH

MF C19 H26 O3

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 133:296594

L72 ANSWER 4 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 258278-77-2 REGISTRY  
CN Estra-1,3,5(10)-triene-2-carbonitrile, 3,17-dihydroxy-17-phenyl-,  
(17.beta.)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN EM 2318  
FS STEREOSEARCH  
MF C25 H27 N O2  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 132:152024

L72 ANSWER 5 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 258278-74-9 REGISTRY  
CN Estra-1,3,5(10)-triene-2-carbonitrile, 3,17-dihydroxy-17-propyl-,  
(17.beta.)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN EM 2132  
FS STEREOSEARCH  
MF C22 H29 N O2  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 132:152024

L72 ANSWER 6 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 258278-49-8 REGISTRY  
CN Estra-1,3,5(10)-triene-2-carbonitrile, 3,17-dihydroxy-17-(phenylmethyl)-,  
(17.beta.)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN EM 1836  
FS STEREOSEARCH  
MF C26 H29 N O2  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:152024

L72 ANSWER 7 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 229635-01-2 REGISTRY  
CN 19-Norpregna-1,3,5(10),20-tetraene-3,17-diol, 2-methoxy-, (17.alpha.)-  
(9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C21 H28 O3  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:195698

REFERENCE 2: 131:88084

L72 ANSWER 8 OF 64 REGISTRY COPYRIGHT 2002 ACS

RN 192062-30-9 REGISTRY

CN Estra-1,3,5(10)-trien-3-ol, 17-amino-2-ethoxy-, (17.beta.)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C20 H29 N O2

CI COM

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 127:95444

L72 ANSWER 9 OF 64 REGISTRY COPYRIGHT 2002 ACS

RN 192062-27-4 REGISTRY

CN Estra-1,3,5(10)-trien-3-ol, 17-amino-2-ethoxy-, hydrochloride, (17.beta.)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C20 H29 N O2 . Cl H

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

CRN (192062-30-9)

Absolute stereochemistry.




● HCl

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 127:95444

L72 ANSWER 10 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 192062-18-3 REGISTRY  
CN Estra-1,3,5(10)-triene-3,6,17-triol, 2-ethoxy-, (6.alpha.,17.beta.)- (9CI)  
(CA INDEX NAME)  
FS STEREOSEARCH  
MF C20 H28 O4  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:322044

REFERENCE 2: 127:95444

L72 ANSWER 11 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 192062-17-2 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 6-amino-2-ethoxy-, (17.beta.)- (9CI)  
(CA INDEX NAME)  
FS STEREOSEARCH  
MF C20 H29 N O3  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 127:95444

L72 ANSWER 12 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 192062-07-0 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(2,2,2-trifluoroethoxy)-, (17.beta.)-  
(9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C20 H25 F3 O3  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1967 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:322044

REFERENCE 2: 129:245330


REFERENCE 3: 127:95444

L72 ANSWER 13 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 161762-25-0 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(3-aminopropyl)-, (17.beta.)- (9CI)  
(CA INDEX NAME)  
FS STEREOSEARCH  
MF C21 H31 N O2



SR CA  
LC STN Files: CA, CAPLUS

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 122:187857

L72 ANSWER 14 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 161762-24-9 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(3-hydroxypropyl)-, (17.beta.)- (9CI)  
(CA INDEX NAME)  
FS STEREOSEARCH  
MF C21 H30 O3  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1967 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:31870


REFERENCE 2: 124:289981

REFERENCE 3: 122:187857

L72 ANSWER 15 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 161762-23-8 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(2-aminoethyl)-, (17.beta.)- (9CI)  
(CA INDEX NAME)  
FS STEREOSEARCH  
MF C20 H29 N O2

SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 125:105405

REFERENCE 2: 122:187857

L72 ANSWER 16 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 161762-22-7 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(2-hydroxyethyl)-, (17.beta.)- (9CI)  
(CA INDEX NAME)  
FS STEREOSEARCH  
MF C20 H28 O3  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1967 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:31870


REFERENCE 2: 124:289981

REFERENCE 3: 122:187857

L72 ANSWER 17 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 161762-21-6 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(aminomethyl)-, hydrochloride,  
(17.beta.)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH  
 MF C19 H27 N O2 . Cl H  
 SR CA  
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.



● HCl

1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 122:187857

L72 ANSWER 18 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 156669-41-9 REGISTRY  
 CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 4-bromo-2-methoxy-,  
 (17.alpha.)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-Methoxy-4-bromo-17.alpha.-ethynylestradiol

CN 4-Bromo-2-methoxyethynylestradiol


FS STEREOSEARCH

MF C21 H25 Br O3

SR CA

LC STN Files: CA, CAPLUS, TOXLIT

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 121:100057

L72 ANSWER 19 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 153654-78-5 REGISTRY

CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 2-(hydroxymethyl)-,  
 (17.alpha.)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C21 H26 O3  
 SR CA  
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: .120:192069

L72 ANSWER 20 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 144216-19-3 REGISTRY  
 CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2,4-bis(hydroxymethyl)- (9CI) (CA  
 INDEX NAME)  
 FS STEREOSEARCH  
 MF C20 H26 O4  
 SR CA  
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 117:212773

L72 ANSWER 21 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 144216-18-2 REGISTRY  
 CN 19-Norpregna-1,3,5(10)-trien-20-yne-2,4-dimethanol, 3,17-dihydroxy-,

(17.alpha.)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C22 H28 O4  
 SR CA  
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1967 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 120:192069

REFERENCE 2: 117:212773

L72 ANSWER 22 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 144216-17-1 REGISTRY  
 CN Estra-1,3,5(10)-triene-2,4-dimethanol, 3,17-dihydroxy-, (17.alpha.)- (9CI)  
 (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C20 H28 O4  
 SR CA  
 LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1967 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 120:192069

REFERENCE 2: 117:212773

L72 ANSWER 23 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 141056-21-5 REGISTRY  
CN Estra-1,3,5(10)-trien-17-one, 4-fluoro-3-hydroxy-2-methoxy- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 2-Methoxy-4-fluoroestrone  
CN 4-Fluoro-2-methoxyestrone  
FS STEREOSEARCH  
MF C19 H23 F O3  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 116:207984

L72 ANSWER 24 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 119829-59-3 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(1-hydroxy-1-methylethyl)-, (17.beta.)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C21 H30 O3  
SR CA  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT  
(\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 110:154665

L72 ANSWER 25 OF 64 REGISTRY COPYRIGHT 2002 ACS

RN 111443-37-9 REGISTRY

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Estrone, 2-(hydroxymethyl)- (6CI)


FS STEREOSEARCH

MF C19 H24 O3

SR CAOLD

LC STN Files: CA, CAOLD, CAPLUS

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 120:192069

L72 ANSWER 26 OF 64 REGISTRY COPYRIGHT 2002 ACS

RN 98543-85-2 REGISTRY

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-(1-methyl-2-propenyl)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-(1-methylallyl)- (7CI)

FS STEREOSEARCH


DR 175414-64-9

MF C22 H28 O2

SR CAOLD

LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS  
(\*File contains numerically searchable property data)

Absolute stereochemistry.



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 124:260811

L72 ANSWER 27 OF 64 REGISTRY COPYRIGHT 2002 ACS

RN 97515-50-9 REGISTRY

CN Estra-1,3,5(10)-triene-3,17-diol, 4-bromo-2-methoxy-, (17.beta.)- (9CI)  
(CA INDEX NAME)

## OTHER NAMES:

CN 4-Bromo-2-methoxyestradiol


FS STEREOSEARCH

MF C19 H25 Br O3

SR CA

LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT, TOXCENTER, TOXLIT  
(\*File contains numerically searchable property data)

Absolute stereochemistry.



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 111:233338

REFERENCE 2: 103:65176

L72 ANSWER 28 OF 64 REGISTRY COPYRIGHT 2002 ACS

RN 97515-47-4 REGISTRY

CN Estra-1,3,5(10)-triene-3,17-diol, 4-fluoro-2-methoxy-, (17.beta.)- (9CI)  
(CA INDEX NAME)

## OTHER NAMES:

CN 4-Fluoro-2-methoxyestradiol

FS STEREOSEARCH


MF C19 H25 F O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT

Absolute stereochemistry.





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 105:146466

REFERENCE 2: 103:65176

L72 ANSWER 29 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 94761-90-7 REGISTRY  
CN Estra-1,3,5(10)-trien-17-one, 2-methoxy-4-methyl- (7CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C20 H26 O2  
LC STN Files: BEILSTEIN\*, CAOLD  
(\*File contains numerically searchable property data)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L72 ANSWER 30 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 94440-60-5 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(hydroxymethyl)-, (17.beta.)- (9CI)  
(CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Estra-1,3,5(10)-triene-3,17.beta.-diol, 2-(hydroxymethyl)- (7CI)  
FS STEREOSEARCH  
MF C19 H26 O3  
LC STN Files: CA, CAOLD, CAPLUS, TOXCENTER, TOXLIT

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

6 REFERENCES IN FILE CA (1967 TO DATE)  
 6 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:31870  
 REFERENCE 2: 130:262306  
 REFERENCE 3: 125:105405  
 REFERENCE 4: 124:289981  
 REFERENCE 5: 122:187857  
 REFERENCE 6: 120:192069

L72 ANSWER 31 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 77736-30-2 REGISTRY  
 CN Estra-1,3,5(10)-triene-6,17-dione, 2-methoxy- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C19 H22 O3  
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 95:7573

L72 ANSWER 32 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 77736-29-9 REGISTRY  
 CN Estra-1,3,5(10)-trien-6-one, 17-hydroxy-2-methoxy-, (17.beta.)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH  
MF C19 H24 O3  
LC STN Files: CA, CAPLUS

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 95:7573

L72 ANSWER 33 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 77736-24-4 REGISTRY  
CN Estra-1,3,5(10)-triene-6,17-dione, 3-hydroxy-2-methoxy- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C19 H22 O4  
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 97:163313

REFERENCE 2: 95:7573

L72 ANSWER 34 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 69833-94-9 REGISTRY  
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-methoxy-, O-methyloxime (9CI) (CA INDEX NAME)

FS STEREOSEARCH  
MF C20 H27 N O3  
LC STN Files: SPECINFO


Absolute stereochemistry.  
Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L72 ANSWER 35 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 69540-63-2 REGISTRY  
CN Estra-1,3,5(10)-trien-6-one, 3,17-dihydroxy-2-methoxy-, (17.beta.)- (9CI)  
(CA INDEX NAME)  
FS STEREOSEARCH  
DR 77736-21-1  
MF C19 H24 O4  
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

6 REFERENCES IN FILE CA (1967 TO DATE)  
6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:295993  
REFERENCE 2: 97:163313  
REFERENCE 3: 95:7573  
REFERENCE 4: 92:144013  
REFERENCE 5: 92:108010  
REFERENCE 6: 90:121859

L72 ANSWER 36 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 69505-03-9 REGISTRY  
CN Estra-1,3,5(10)-trien-17-one, 2-methoxy-, (.+-.)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C19 H24 O2  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, GMELIN\*  
(\*File contains numerically searchable property data)

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 93:114810

REFERENCE 2: 90:121861

L72 ANSWER 37 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 65968-97-0 REGISTRY  
CN Estra-1,3,5(10)-triene-3,4,17-triol, 2-methoxy-, (17.beta.)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C19 H26 O4  
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 88:136839

L72 ANSWER 38 OF 64 REGISTRY COPYRIGHT 2002 ACS

RN 65968-96-9 REGISTRY  
 CN Estra-1,3,5(10)-trien-17-one, 3,4-dihydroxy-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C25 H28 O4  
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 88:136839

L72 ANSWER 39 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 59939-20-7 REGISTRY  
 CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, hydrogen sulfate, (17.beta.)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C19 H26 O3 . x H2 O4 S  
 LC STN Files: CA, CAPLUS

CM 1


CRN 7664-93-9  
 CMF H2 O4 S



CM 2

CRN 362-07-2  
 CMF C19 H26 O3

Absolute stereochemistry.




1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 84:148461

L72 ANSWER 40 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 58562-34-8 REGISTRY  
CN Estra-1,3,5(10)-trien-17-one, 3,4-dihydroxy-2-methoxy- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 2,3,4-Trihydroxy-1,3,5(10)-estratrien-17-one 2-methyl ether  
FS STEREOSEARCH  
MF C19 H24 O4  
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1967 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 88:136839

REFERENCE 2: 84:119044

REFERENCE 3: 84:102907

L72 ANSWER 41 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 52691-63-1 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(1-methyl-2-propenyl)-, [2(S),17.beta.]- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C22 H30 O2  
LC STN Files: BEILSTEIN\*, CA, CAPLUS  
(\*File contains numerically searchable property data)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 80:146402

L72 ANSWER 42 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 52619-49-5 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(1-methyl-2-propenyl)-, (17.beta.)-  
(9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C22 H30 O2  
LC STN Files: BEILSTEIN\*, CA, CAPLUS  
(\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 80:146402

L72 ANSWER 43 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 51933-36-9 REGISTRY  
CN Estra-1,3,5(10)-triene-17-one, 2-(2-chloro-2-propenyl)-3-hydroxy- (9CI)  
(CA INDEX NAME)  
FS STEREOSEARCH  
MF C21 H25 Cl O2  
LC STN Files: BEILSTEIN\*, CA, CAPLUS  
(\*File contains numerically searchable property data)

Absolute stereochemistry.






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 81:91784

L72 ANSWER 44 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 42028-20-6 REGISTRY  
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-methoxy-4-methyl- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 2-Methoxy-4-methylestrone  
FS STEREOSEARCH  
MF C20 H26 O3  
LC STN Files: CA, CAPLUS, TOXLIT

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 79:27594

L72 ANSWER 45 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 42028-17-1 REGISTRY  
CN Estra-1,3,5(10)-triene-1,17-diol, 2-methoxy-4-methyl-, (17.beta.)- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Estra-1,3,5(10)-triene-1,17.beta.-diol, 2-methoxy-4-methyl- (7CI)  
FS STEREOSEARCH  
MF C20 H28 O3  
LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, TOXLIT  
(\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 79:27594

L72 ANSWER 46 OF 64 REGISTRY COPYRIGHT 2002 ACS

RN 41259-43-2 REGISTRY

CN Estra-1,3,5(10)-triene-3,17-diol, 2-azido-, (17.beta.)- (9CI) (CA INDEX NAME)

OTHER NAMES:


CN 2-Azidoestradiol

FS STEREOSEARCH

MF C18 H23 N3 O2

LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, TOXLIT

Absolute stereochemistry.



7 REFERENCES IN FILE CA (1967 TO DATE)  
 7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 118:96907

REFERENCE 2: 101:123208

REFERENCE 3: 96:116050

REFERENCE 4: 94:99013


REFERENCE 5: 91:168869

REFERENCE 6: 80:78582

REFERENCE 7: 79:137346

L72 ANSWER 47 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 41164-50-5 REGISTRY  
CN Estra-1,3,5(10)-trien-17-one, 2-azido-3-hydroxy- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 2-Azidoestrone  
FS STEREOSEARCH  
MF C18 H21 N3 O2  
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT

Absolute stereochemistry.




6 REFERENCES IN FILE CA (1967 TO DATE)  
6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 118:96907  
REFERENCE 2: 94:99013  
REFERENCE 3: 92:53642  
REFERENCE 4: 91:168869  
REFERENCE 5: 80:78582  
REFERENCE 6: 79:137346

L72 ANSWER 48 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 35577-55-0 REGISTRY  
CN Estra-1,3,5(10)-trien-17-ol, 2-methoxy-4-methyl-, (17.beta.)- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Estra-1,3,5(10)-trien-17.beta.-ol, 2-methoxy-4-methyl- (6CI, 7CI)  
OTHER NAMES:  
CN 2-Methoxy-4-methylestratriene-17.beta.-ol  
FS STEREOSEARCH  
MF C20 H28 O2  
LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, TOXLIT  
(\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1967 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 79:27594

REFERENCE 2: 76:113417

L72 ANSWER 49 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 31559-55-4 REGISTRY  
 CN 19-Nor-17.alpha.-pregna-1,3,5(10)-triene-2-carbonitrile, 3,17-dihydroxy-  
 (8CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C21 H27 N O2  
 LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 74:112314

L72 ANSWER 50 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 27293-73-8 REGISTRY  
 CN Estra-1,3,5(10)-trien-17-one, 2-methoxy- (8CI, 9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 DR 27293-89-6  
 MF C19 H24 O2  
 LC STN Files: BEILSTEIN\*, GMELIN\*, TOXLIT  
 (\*File contains numerically searchable property data)


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L72 ANSWER 51 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 22145-26-2 REGISTRY  
 CN Estra-1,3,5(10)-triene-3,17-diol, 2-(phenylmethoxy)-, (17.beta.)- (9CI)  
 (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Estra-1,3,5(10)-triene-3,17.beta.-diol, 2-(benzyloxy)- (8CI)  
 FS STEREOSEARCH  
 MF C25 H30 O3  
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1967 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 124:317590


REFERENCE 2: 119:117610

REFERENCE 3: 77:101989.

REFERENCE 4: 70:106759

L72 ANSWER 52 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 17553-16-1 REGISTRY  
 CN Estra-1,3,5(10)-trien-17.beta.-ol, 2-methoxy- (6CI, 7CI, 8CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C19 H26 O2  
 LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1967 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 73:116788

REFERENCE 2: 72:121765

REFERENCE 3: 68:69179

L72 ANSWER 53 OF 64 REGISTRY COPYRIGHT 2002 ACS

RN 16373-38-9 REGISTRY

CN Estra-1,3,5(10)-triene-3,17.beta.-diol, 2-methoxy-1-methyl- (8CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C20 H28 O3

LC STN Files: BEILSTEIN\*, CA, CAPLUS

(\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 67:117038

L72 ANSWER 54 OF 64 REGISTRY COPYRIGHT 2002 ACS

RN 10506-80-6 REGISTRY

CN Estra-1,3,5(10)-trien-17-one, 2-allyl-3-hydroxy- (7CI, 8CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Estrone, 2-allyl- (6CI)


FS STEREOSEARCH

MF C21 H26 O2

LC STN Files: BEILSTEIN\*, CAOLD

(\*File contains numerically searchable property data)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L72 ANSWER 55 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 10506-67-9 REGISTRY  
 CN Estra-1,3,5(10)-triene-3,17.beta.-diol, 2-allyl- (7CI, 8CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C21 H28 O2  
 LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, TOXLIT  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 66:102215

L72 ANSWER 56 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 10332-20-4 REGISTRY  
 CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, (17.alpha.)- (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Estra-1,3,5(10)-triene-3,17.alpha.-diol, 2-methoxy- (8CI)  
 FS STEREOSEARCH  
 MF C19 H26 O3  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, TOXLIT  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 110:166220

REFERENCE 2: 105:146466


L72 ANSWER 57 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 7683-30-9 REGISTRY  
CN 17H-Cyclopenta[a]phenanthren-17-one, 6,7,8,9,11,12,13,14,15,16-decahydro-3-hydroxy-2-methoxy-13-methyl- (8CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C19 H24 O3  
LC STN Files: BEILSTEIN\*  
(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L72 ANSWER 58 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 6564-02-9 REGISTRY  
CN Estra-1,3,5(10)-triene-2-carbonitrile, 3-hydroxy-17-oxo- (7CI, 8CI, 9CI)  
(CA INDEX NAME)  
FS STEREOSEARCH  
MF C19 H21 N O2  
LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, IFICDB, IFIPAT, IFIUDB  
(\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


REFERENCE 1: 113:191714

REFERENCE 2: 74:112314



L72 ANSWER 59 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 6562-00-1 REGISTRY  
 CN Estra-1,3,5(10)-trien-17-one, 2-(1,1-dimethylallyl)-3-hydroxy- (7CI, 8CI)  
 (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C23 H30 O2  
 LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 70:68602

L72 ANSWER 60 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 5976-42-1 REGISTRY  
 CN Estra-1,3,5(10)-triene-2-carbonitrile, 3,17-dihydroxy-, (17.beta.)- (9CI)  
 (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Estra-1,3,5(10)-triene-2-carbonitrile, 3,17.beta.-dihydroxy- (7CI, 8CI)  
 FS STEREOSEARCH  
 MF C19 H23 N O2  
 LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, CASREACT, IFICDB, IFIPAT,  
 IFIUDB  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1967 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 113:191714

REFERENCE 2: 74:112314

L72 ANSWER 61 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 4967-94-6 REGISTRY  
CN Estra-1,3,5(10)-triene, 2-methoxy- (8CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C19 H26 O  
LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS  
(\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1967 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 73:116788

REFERENCE 2: 70:78228

L72 ANSWER 62 OF 64 REGISTRY COPYRIGHT 2002 ACS  
RN 4953-96-2 REGISTRY  
CN Estra-1,3,5(10)-trien-3-ol, 2-methoxy- (7CI, 8CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C19 H26 O2  
LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS  
(\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 70:78228

L72 ANSWER 63 OF 64 REGISTRY COPYRIGHT 2002 ACS

RN 2120-13-0 REGISTRY  
 CN Estra-1,3,5(10)-triene-3,17.beta.-diol, 2,4-diallyl- (7CI, 8CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C24 H32 O2  
 LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, TOXLIT  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 66:102215

L72 ANSWER 64 OF 64 REGISTRY COPYRIGHT 2002 ACS  
 RN 2120-12-9 REGISTRY  
 CN Estra-1,3,5(10)-trien-17-one, 2,4-diallyl-3-hydroxy- (7CI, 8CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Estrone, 2,4-diallyl- (6CI)  
 FS STEREOSEARCH  
 MF C24 H30 O2  
 LC STN Files: BEILSTEIN\*, CAOLD  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

